CADTH is committed to supporting Canada’s health care decision-makers through this challenging and uncertain time.
For evidence, tools, and resources related to COVID-19, visit our COVID-19 Evidence Portal.

 

Begin main content

Search

We found 7176 result(s)

venetoclax (Venclexta)

Last Updated: March 3, 2021
Result type: Reports
Product Line: Reimbursement Review
Generic Name: venetoclax
Indications: In combination with azacitidine or low-dose cytarabine is indicated for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) who are 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.

  • Brand Name: Venclexta
  • Manufacturer: AbbVie Corporation
  • Project Number: PC0239-000
  • Project Status: Active
  • Submission Type: Initial

larotrectinib (Vitrakvi)

Last Updated: December 23, 2020
Result type: Reports
Product Line: Reimbursement Review
Generic Name: larotrectinib
Indications: For the treatment of adult and pediatric patients with solid tumours that: have a neurotrophic tyrosine receptor kinase (NTRK) gene fusion without a known acquired resistance mutation; are metastatic or where surgical resection is likely to result in severe morbidity, and; have no satisfactory treatment options.

  • Brand Name: Vitrakvi
  • Manufacturer: Bayer Inc.
  • Project Number: PC0221-000
  • Project Status: Active
  • Submission Type: Resubmission

Sonidegib (Odomzo) for Basal Cell Carcinoma - Details

Last Updated: March 4, 2021
Result type: Reports
Product Line: Reimbursement Review

  Provide Feedback Provide Feedback on Draft Recommendations Initial Recommendation Issued: March 4, 2021 Feedback Deadline: March 18, 2021 Feedback Template: Stakeholder Feedback on a pERC Initial Recommendation  Submit Feedback  

  • Project Number: PC0215-000

Avelumab (Bavencio) for Urothelial Carcinoma - Details

Last Updated: March 4, 2021
Result type: Reports
Product Line: Reimbursement Review

  Provide Feedback Provide Feedback on Draft Recommendations Initial Recommendation Issued: March 4, 2021 Feedback Deadline: March 18, 2021 Feedback Template: Stakeholder Feedback on a pERC Initial Recommendation  Submit Feedback  

  • Project Number: PC0225-000